ClinicalTrials.gg
RecruitingNCT06743659FH-ALERTUpdated Sep 29, 2026

Computerized Decision Support for Identification and Management of Familial Hypercholesterolemia

An interventional study of Alert-based computerized decision support in Familial Hypercholesterolaemia, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.
Updated Sep 29, 2026Study completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
450
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Hyperlipoproteinemia Type II with a site in United States — 17 open to participants now, 18 under way, 6 of them phase 3. Hyperlipoproteinemia Type II · United States.

Planned enrollment
15th of 68
450 · median 163
Started
2025
with 2 others
No phase
13 of 76
8 open now
Primary completion
2027-03
later than 7 of 17 live
Registered
70th of 76
by date

Among the 76 studies in Hyperlipoproteinemia Type II with a site in United States, this one is the 15th largest by planned enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2025, is one of 13 with no phase, reaches primary completion later than 7 of the 17 other live ones, and was the 70th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

17 of the 76 studies in Hyperlipoproteinemia Type II with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Hyperlipoproteinemia Type II with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if a computer alert can aid clinicians in identifying patients with a genetic type of high cholesterol, called Familial Hypercholesterolemia. The main question it aims to answer is whether the computer alert increases recognition of this high cholesterol disorder.

Read the detailed description

FH-ALERT is a single-center, time-series trial of a patient- and provider-facing EPIC BPA (alert-based CDS tool) to increase diagnosis, LDL-C lowering, and guideline-based therapy of outpatients with presentations consistent with FH. For the first 6 months, the BPA will run in "silent mode", identifying patients with presentations consistent with FH, but not alerting the clinician of record. Following this initial "pre-alert" 6-month period, the BPA will switch to "alert mode" for 18 months, which will provide the on-screen notification to the clinician of record. In other words, consecutive outpatients with presentations consistent with FH will be enrolled over two years: "pre-alert" (silent mode) for 6 months and "alert mode" for 18 months.

03

Conditions studied

  • Familial Hypercholesterolaemia

Keywords

  • Familial Hypercholesterolemia
  • Computerized Decision Support
  • Electronic Alerts
  • High Cholesterol
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥ 18 years old
  • seen in the BWH Endocrinology, Cardiovascular Medicine, and Primary Care Clinics
  • Dutch Lipid Clinic Network score of at least 3 points

Exclusion criteria

Exclusion Criteria:

  • a Familial Hypercholesterolemia diagnosis already documented in the EHR medical history, visit history, or problem list
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
450 participants (estimated)

Study arms

  • No intervention
    Pre-Alert

    In the Pre-Alert phase of 6 months, patients meeting enrollment criteria will be identified but the clinician will not be notified regarding the possible diagnosis of Familial Hypercholesterolemia.

  • Experimental
    Alert

    In the Alert phase of 18 months, an on-screen alert through the Electronic Health Record will notify the ambulatory care clinician of record that the patient has a "definite," "probable," or "possible" diagnosis of FH but has not been recognized as such.

    Device: Alert-based computerized decision support

Interventions

  • DeviceAlert-based computerized decision support

    A program will be designed to run within the Electronic Health Record (EHR) that will identify outpatients with "definite," "probable," or "possible" diagnosis of FH. The BPA will calculate the Dutch Lipid Clinic Network score using the following EHR data: 1. Maximum LDL-C level in the laboratory results 2. Abnormal genetic testing for FH in the laboratory results 3. Medical history or problem list entry for tendinous xanthomata or arcus cornealis 4. Medical history, visit diagnosis, or problem list entry of premature CAD, cerebrovascular disease, or PAD 5. Family history of premature CAD, cerebrovascular disease, or PAD In the Alert phase, an on-screen alert will notify the ambulatory care clinician of record that the patient has a "definite," "probable," or "possible" diagnosis of FH. ambulatory care clinician will have the opportunity to proceed to an order template through which a referral for specialty care focused on evaluation and management of FH can be made.

    Also known as: Best Practice Advisory, Computer Alert

06

What researchers measure

Primary outcomes

  1. Frequency of documented FH diagnosis

    We will review the medical history, visit diagnosis, and problem list sections of the Electronic Health Record (EPIC) to make this determination of diagnosis of Familial Hypercholesterolemia.

    Time frame: 6 Months

Secondary outcomes

  1. Mean Change in LDL-C

    Mean change in LDL-C levels within 6 months following triggering of the BPA compared with the most recent LDL-C prior to the clinic visit in outpatients with presentations consistent with FH ("definite," "probable," or "possible" Dutch Lipid Clinic Network score).

    Time frame: 6 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Will provide data upon reasonable request after publication of study.

Supporting information: Study protocol, Clinical study report, Analytic code

Time frame: After completion of the study for a period of 10 years

Access criteria: Investigators with a scientifically sound reason for accessing the data upon reasonable request

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Mar 2027, 23 months after the start.

Of 35 non-industry interventional studies with no phase under Hyperlipoproteinemia Type II, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 23 months is below that.

Counting every sponsor, half of 37 studies reached it within 29 months; a quarter within 12 and three quarters within 41.

Completion moved once since we started tracking on Sep 25, 2026: Dec 2027 → Nov 2027, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2024
First posted
Dec 20, 2024
StartActual
Apr 1, 2025
Primary completionEst.
Mar 30, 2027
CompletionEst.
Nov 30, 2027was Dec 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Dec 31, 2027→Nov 30, 2027
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Study completion Dec 31, 2027→Nov 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06743659
Responsible party
Gregory Piazza, MD, MS (Staff Physician, Brigham and Women's Hospital) — Principal investigator
First posted
Dec 20, 2024
Start date
Apr 1, 2025
Primary completion
Mar 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Gregory Piazza, MD, MS
Contact
gpiazza@partners.org
6177326984

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion